5 ms·
I'm going to try to raise money to bring an IP-unrestricted anticancer compound up to the point of FDA clinical trials. (i.e. as far as you can go without invo
by dnautics 13y ago
I'm going to try to raise money to bring an IP-unrestricted anticancer compound up to the point of FDA clinical trials. (i.e. as far as you can go without involving humans). I'm pretty sure that I'll be using crowdhoster as the platform.
- Blahah 13y agoThis is awesome. Are you developing it unfunded at the moment?
- dnautics 13y agoWork on it was discontinued when my boss quit her job at the university of maryland. The 1 year patenting period has expired, I have no love for patents anyways, so I'm going to generate several analogs and register them as something called "US Statutory Invention Registration" which prevents them from being patented. I have her blessing (not that I would need it from a legal POV) to continue work on this project. Since then I've been accruing a lot of synthetic biology experience (I'm currently probably the most experienced person in the world at a new technique called "gibson assembly" - I've done upwards of 100 successful gibson assemblies on a wide range of molecular biology targets), which should help the process go even more smoothly. Details are at: http://indysci.org http://indysci.org, currently we're waiting for the IRS to approve our application for 501(c)3 status before launching our fundraising. Our target launch date is January 2014
- Blahah 13y agoThat's an awful lot of Gibson! What tools are you using to design your constructs? I briefly joined the developers of Gibthon (FOSS gibson assembly design software; http://gibthon.org/ http://gibthon.org/) last year - they will be thrilled to hear if you use it. In fact, if you would be willing to share some of your experience, no doubt it would be invaluable for improving the design tools. We've also got lots of people in our department doing lots of Gibson assembly. If you ever want to compare notes or anything... my email is in profile. How are you doing for computational biologists?
- dnautics 13y agoWe use CLC. Basically the workflow is 1) find sequences that you want to stitch together. 2) build a draft plasmid. 3) make fine tuning changes (making sure RBSes are ok, we aren't stomping on terminators or promoters, etc, add mutations if we want). 4) annotate primer regions. 5) cut and paste into IDT's primer orderer. The bulk of my gibson assemblies (about 50 of the ~100 that I've done personally, plus 12 that my college intern last year did, and 13 going on 48+ that my intern this summer is doing) are for site-directed mutagenesis; quikchange blows, and the plasmid I'm playing with is 20kb anyways, with 12kb of mission critical DNA. The general scheme is: design 2 mutagenic primers, 2 PCR using primers that flank a pair of unique restriction sites near our site, then gibson the left hand and right hand products with a stock of pre-digested plasmid. Since bacterial plasmid propagation is "error-free", we don't bother sequencing all but 1kb or so of the final product - saves on cost - and our plan is to do shotgun sequencing of all of the plasmids, barcoded, with ionTorrent when we're done. We're also doing combinatorial installation of promoters that my boss' intern has done (27 constructs) - that I've partially supervised. Among the other things that I've done are gene fusions, leader sequence deletions, moving around restriction sites, swapping plasmid backbones, assembly of complex, highly repetitive sequences, and we attempted (but only partially succeeded at) capturing a eukaryotic chromosome by the telomeres. We cut a lot of corners, but for NEB's sake (I like them) I'm not going to discuss exactly what those corners are, quite yet. Even with ours sloppiness, it works nearly every time, often with 8/8 correct (and sometimes you have to screen 48 to get one, but that's rare and I haven't had that happen in about a year or so). My general philosophy is the more sloppy you can get away with being, the more robust your procedure is - I like gibson assembly because I can teach it to an undergrad in a week and have them rip roaring on a project. There are lesser known properties of gibson assembly (and this is in the original paper if you read it carefully, which most people don't) - you can have inexact ends, for example, if you want to have a template that is released using restriction enzymes - the 3' exonuclease activity of the polymerase will remove it and create a seamless construct with no evidence of the former restriction site. I have to warn: This would be hard (but not impossible) to implement in a design suite, and nearly impossible for automated design unless you are using exactly the same RE protocol each time. Slight disclaimer - I'm a coworker of Dan Gibson's, so take my evangelism with a little bit of a grain of salt. I will also say, that there are plasmids that you absolutely can't gibson clone into and we don't know why. pBR322 tet marker is an unclonable position, for example. Finally:, we don't really use computational biologists. Actually, we're designing enzyme variations from first principles and previous literature report, without appealing to simulation or model, with quite a bit of success.
- ajaymehta 13y agoHey! That's so awesome to hear, thank you. Please feel free to reach out to me directly: ajay@crowdtilt.com
- rdl 13y agoWould microryza also make sense (for the lab part, and then crowdhoster for other parts?)
- dnautics 13y agono. Microryza only works with people at accredited research institutes. It's also not a 501(c)3.
- shoyer 13y agoHow do you plan to eventually bring your compound to market without IP rights? As I'm sure you know, clinical trials are very expensive, and investors expect IP rights to guarantee a return on their investment.
- dnautics 13y agoVery good question. The uncomfortable thing for me to admit is that there is no plan yet (otherwise I'd have done it as a for-profit company). I have several ideas about how it might happen. It could start off as a veterinary drug. Clinical trials might happen in a country where it's less expensive. A brave generics company could stump for it anyway. There is no ROI guaranteed with ANY compound (100 different ways it could fail), and not being IP'd doesn't mean you 'don't get a ROI', it means you have to work harder, be more patient, and be more of a manufacturing badass to get that ROI. I'm trying to stack the deck here - the compound is natural product-inspired (which empirically means the likelihood of working is higher), and it should be relatively easy to manufacture.